Premium
Five‐year study of quality of life in myotonic dystrophy
Author(s) -
Peric S.,
Vujnic M.,
Dobricic V.,
Marjanovic A.,
Basta I.,
Novakovic I.,
Lavrnic D.,
RakocevicStojanovic V.
Publication year - 2016
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/ane.12549
Subject(s) - medicine , myotonic dystrophy , quality of life (healthcare) , physical therapy , weakness , cohort , sf 36 , muscular dystrophy , rating scale , muscle weakness , cohort study , pediatrics , disease , health related quality of life , surgery , psychology , developmental psychology , nursing
Background – Myotonic dystrophy type 1 ( DM 1) is the most common muscular dystrophy in adults. There is a complete lack of studies that assessed quality of life (QoL) trajectory during time in DM 1 cohorts. Aim – To analyze changes of QoL in patients with DM 1 during a 5‐year follow‐up period and to assess responsiveness of the SF ‐36 questionnaire. Patients and Method – At the baseline, this study comprised 84 DM 1 patients, of whom 62 were retested after the mean period of 64.2 ± 3.9 months. Severity of muscular weakness was assessed using the Muscular Impairment Rating Scale ( MIRS ). Patients completed Serbian version of the SF ‐36 questionnaire as a measure of health‐related QoL. Results – After 5 years, MIRS score of our DM 1 patients showed significant progression of 0.5 grade ( P < 0.01). All mental subdomains, role physical, and total SF ‐36 scores significantly improved after 5 years ( P < 0.01). Unexpectedly, worsening of muscular weakness from mild to severe was in association with improvement of QoL. Conclusion – QoL improved in our cohort of DM 1 patients during a 5‐year period despite the progression of the disease. SF ‐36 should be used with caution as a patient‐reported outcome measure in DM 1 clinical trials.